ArticleJournal of applied clinical medical physics2026
Dosimetric comparison of TG-43 formalism and HU-based AcurosBV algorithms in HDR brachytherapy for head-and-neck superficial lesions with H.A.M. applicators.
Article in Journal of applied clinical medical physics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTG-43 formalism assumes homogeneous water media, potentially overlooking anatomical heterogeneities that affect dose accuracy. AcurosBV, a model-based dose calculation algorithm, accounts for tissue and material heterogeneities. This study evaluates their dosimetric differences in high-dose-rate (HDR) brachytherapy using Harrison-Anderson-Mick (H.A.M.) applicators. PURPOSE: To compare dose-volume histogram (DVH) metrics calculated using TG-43 formalism and AcurosBV in patients treated with HDR brachytherapy using H.A.M. applicators for superficial lesions in the head and neck regions.
methodsTwenty patients (17 nasal, 3 non-nasal) received HDR brachytherapy with H.A.M. applicators to a total dose of 40 Gy in eight fractions. Original plans calculated with TG-43 formalism were retrospectively re-calculated using AcurosBV (Eclipse v16.1), incorporating Hounsfield unit-based heterogeneity corrections with dose-to-medium reporting. Planning target volumes (PTVs) were contoured by radiation oncologists; organs at risk (OARs) including brain, eyes, lens, optical nerve and skin were auto-segmented using AutoContour (Radformation Inc., NY). DVH metrics (mean dose, D90%, V100%, V150%, V200%, D0.1cc, D0.2cc, D1cc and D2cc) were compared. The isodose distributions from both algorithms were also evaluated slice by slice. Statistical significance was assessed using a paired Student's t-test (p < 0.05).
resultsAcurosBV consistently reported lower DVH value in PTV than TG-43. The average PTV mean dose was 48.65 ± 1.22 Gy (AcurosBV) versus 50.78 ± 1.40 Gy (TG-43), with significant difference in V100 (-6.43 ± 0.95%, p < 0.003). OAR dose differences were modest (∼1.5%) except for the skin, which showed larger reductions (∼4-5% in D0.1cc-D2cc, p < 10
conclusionAcurosBV yielded lower and anatomically informed dose estimates compared with TG-43 in HDR brachytherapy using H.A.M. applicators. These results support clinical adoption of model-based algorithms but warrant caution, as dosimetric differences and prior TG-43 experience may affect existing dose constraints and clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.